65,437 trials
Chronic Myelogenous Leukemia
Primary: Number of Participants With Major Molecular Response (MMR) Rate at 24 Weeks — 40; 10 Participants — p=0.029
Asthma · Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HRS-D) Change Scores — -8.39 units on a scale
Pain, Musculoskeletal
Primary: Opioid Usage During the Postoperative Hospitalization — 30.3; 30.8 Morphine milligram equivalents (MME)/day
Postsurgical Pain
Primary: Time-specific Mean Pain Intensity Scores (NRS) at Time 96 Hours for CA-008 vs. Placebo — 3.8; 5.1; 4.9; 4.8 scores on a scale — p=0.276
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) — -2.37; -2.46; -1.86 Percentage of HbA1c — p=<0.001
Heart Failure · Arrhythmias, Cardiac · Sudden Cardiac Death
Primary: Number of Participants With Ventricular Arrhythmia Associated Symptoms - ICD/CRT-D Cohorts — 3; 8 Participants
Progressive Multiple Sclerosis
Primary: Comfortable Walking Speed — .45; .60; .52; .67 meters per second — p=.405
Alopecia Areata
Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale
Bioelectrical Impedance Measurement of Healthy Adults
Primary: SMM — 0.34 kg
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) — -2.43; -2.58; -1.44 Percentage of HbA1c — p=<0.001
Thrombotic Microangiopathies · Hematologic Diseases
Primary: The Incidence of TA-TMA. — 5; 15 Participants
Healthy Elderly
Primary: Total Body Water — 1.85 liter
Low Back Pain · Back Pain · Lumbar Pain
Primary: Relative Value Unit (RVU) for Spine-related Interventions — 3.53; 3.56 spine-related RVU — p=0.54
Hepatitis B Vaccine
Primary: Anti-HBs Seroconversion Rate at Month 7 — 118; 132 Participants
Hepatitis B, Chronic
Primary: Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 240 — 6.045 Events per person-year